Despite losing a couple of Big Pharma collaborators, Dewpoint Therapeutics is gearing up to finally take its lead biologic condensates into the clinic. But the biotech will need to clear out 18 unwanted roles and narrow its pipeline to make space for the right candidates.
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS
Patent applications reinforce Dewpoint™s leadership in the discovery of condensate-modifying drugs (c-mods) to treat diseases of high unmet needNew first-in-class composition of matter targeting...
PARTNERSHIP TO ACCELERATE DEWPOINT™S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC™S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY...
BOSTON and GLASGOW, Scotland, Sept. 12, 2023 /PRNewswire/ -- Dewpoint Therapeutics and Chemify today announced a partnership to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify's programmable chemistry platform against condensate targets of interest in Dewpoint's oncology and neurodegeneration pipeline.
Novo Nordisk and Dewpoint Therapeutics are partnering up in efforts to treat insulin resistance and diabetic complications, with the Danish Big Pharma offering up the possibility of $745 million in biobucks.
BOSTON, March 22, 2023 /PRNewswire/ -- Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify drug candidates using Dewpoint's discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications.
Dewpoint Therapeutics Granted Second Breakthrough Condensates Platform Technology Patent by US Patent Office
A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery....
Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Michael Wagner, Ph.D., as Senior Vice President of Chemistry and Drug Discovery. Dr. Wagner has a successful track record of building and leading drug discovery organizations and delivering high quality candidates for clinical development. He will be based in Germany.